Hospital admissions for Herpes Zoster in Portugal between 2000 and 2010;Internamentos hospitalares por Herpes Zoster em Portugal entre 2000 e 2010

Acta Medica Portuguesa

Volumn 26, Issue 5, 2013, Pages 531-536

  Mesquita, Margarida ^a,c   Froes, Filipe ^b,c  

^a Centro Hospitalar Lisboa Norte ^*

^b HOSPITAL PULIDO VALENTE   (Portugal)

^c UNIVERSIDADE NOVA DE LISBOA   (Portugal)

Author keywords

Herpes Zoster; Hospitalization length of stay; Patient admission; Patient discharge; Portugal

Indexed keywords

ADOLESCENT; ADULT; AGE; AGED; ARTICLE; CHILD; FEMALE; HERPES ZOSTER; HERPES ZOSTER OPHTHALMICUS; HIGH RISK POPULATION; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; IMMUNOCOMPROMISED PATIENT; INCIDENCE; INFANT; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; NEWBORN; PORTUGAL; POSTHERPETIC NEURALGIA; PRESCHOOL CHILD; RETROSPECTIVE STUDY; SCHOOL CHILD; VIRUS MENINGITIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; FEMALE; HERPES ZOSTER; HUMANS; INFANT; MALE; MIDDLE AGED; PATIENT ADMISSION; PORTUGAL; RETROSPECTIVE STUDIES; TIME FACTORS; YOUNG ADULT;

EID: 84887155592     PISSN: 0870399X     EISSN: 16460758     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Lungu O, Annunziato PW, Gershon A, Staugaitis SM, Josefson D, LaRussa P, et al. Reactivated and latent varicella-zoster virus in human dorsal root ganglia. Proc Natl Acad Sci USA. 1995;92:10980-4.
2. Lukas K, Edte A, Bertrand I. The impact of herpes zoster and post-herpetic neuralgia on quality of life: patient-reported outcomes in six European countries. J Public Health. 2012;20:441-51.
3. Arvin A. Aging, immunity, and the varicella-zoster virus. N Engl J Med. 2005;352:2266-7.
4. Schmader K, Gnann JW Jr, Watson CP. The epidemiological, clinical, and pathological rationale for the herpes zoster vaccine. J Infect Dis. 2008;197:S207-S15.
5. Schmader K. Herpes zoster in older adults. Clin Infect Dis. 2001;32:1481-6.
6. Schmader KE. Epidemiology and impact on quality of life of postherpetic neuralgia and painful diabetic neuropathy. Clin J Pain. 2002;18:350-4.
7. Gauthier A, Breuer J, Carrington D, Martin M, Rémy V. Epidemiology and cost of herpes zoster and post-herpetic neuralgia in the United Kingdom. Epidemiol Infect. 2009;137:38-47.
8. Yawn BP, Saddier P, Wollan PC, St Sauver JL, Kurland MJ, Sy LS. A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clin Proc. 2007;82:1341-9.
9. Donahue JG, Choo PW, Manson JE, Platt R. The incidence of herpes zoster. Arch Intern Med. 1995;155:1605-9.
10. Brisson M, Edmunds WJ. Epidemiology of Varicella-Zoster Virus in England and Wales. J Med Virol. 2003;70:S9-14.
11. Lin YH, Huang LM, Chang IS. Disease burden and epidemiology of herpes zoster in prevaccine Taiwan. Vaccine. 2010;28:1217-20.
12. Scott FT, Leedham-Green ME, Barrett-Muir WY, Hawrami K, Gallagher WJ, Johnson R, et al. A study of shingles and the development of postherpetic neuralgia in East London. J Med Virol. 2003;70:S24-S30.
13. Volpi A. Severe complications of herpes zoster. Herpes. 2007;14:S35-9.
14. Gialloreti LE, Merito M, Pezzotti P, Naldi L, Gatti A, Beillat M, et al. Epidemiology and economic burden of herpes zoster and post-herpetic neuralgia in Italy: A retrospective, population-based study. BMC Infect Dis. 2010;10:230.
15. Arnou R, Fiquet A, Thomas A, Sadorge C. Immunogenicity and safety of Zostavax® approaching expiry potency in individuals aged ≥ 50 years. Hum Vaccin. 2011;7:1060-5.
16. Gilden D. Efficacy of live zoster vaccine in preventing zoster and postherpetic neuralgia. J Intern Med. 2011;269:496-506.
17. Zussman J, Young L. Zoster vaccine live for the prevention of shingles in the elderly patient. Clin Interv Aging. 2008;3:241-50.
18. Schmader KE, Johnson GR, Saddier P, Ciarleglio M, Wang WW, Zhang JH, et al. Effect of a zoster vaccine on herpes zoster-related interference with functional status and health-related quality of life measures in older adults. J Am Geriatr Soc. 2010;58:1634-41.
19. Brisson M, Pellissier JM, Camden S, Quach C, De Wals P. The potential cost-effectiveness of vaccination against herpes zoster and post-herpetic neuralgia. Hum Vaccin. 2008;4:238-45.
20. Pellissier JM, Brisson M, Levin MJ. Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Vaccine. 2007;25:8326-37.
21. van Hoek AJ, Gay N, Melegaro A, Opstelten W, Edmunds WJ. Estimating the cost-effectiveness of vaccination against herpes zoster in England and Wales. Vaccine. 2009;27:1454-67.
22. van Lier A, van Hoek AJ, Opstelten W, Boot HJ, de Melker HE. Assessing the potential effects and cost-effectiveness of programmatic herpes zoster vaccination of elderly in the Netherlands. BMC Health Serv Res. 2010;10:237.
23. Supreme Health Council. Vaccination Plan 2010-Evidence-based recommendations of the Supreme Health Council. Copenhagen:SHC; 2009.
24. Pharmaceutical Benefits Advisory Committee-Public Summary Document-March 2008 PBAC Meeting. Adelaide:PBAC; 2008.
25. Greek Ministry of Health. 2012 National Vaccination Programme for Adults. Athens: GMH; 2011.
26. Instituto Nacional de Estatística. Estimativas Provisórias de População Residente, Portugal, NUTS II, NUTS III e Municípios. Lisboa: Instituto Nacional de Estatística. [Consultado em 2012 Jul 2]. Disponível em https://www.ine.pt.
27. Stein AN, Britt H, Harrison C, Conway EL, Cunningham A, Macintyre CR, et al. Herpes Zoster burden of illness and health care resource utilization in the Australian population aged 50 years and older. Vaccine. 2009;27:520-9.
28. Lin F, Hadler JL. Epidemiology of primary varicella and herpes zoster hospitalizations: The pre-varicella vaccine era. J Infect Dis. 2000;181:1897-905.
29. Gabutti G, Serenelli C, Sarno O, Marconi S, Corazza M, Virgili A. Epidemiologic features of patients affected by herpes zoster: Database analysis of the Ferrara University Dermatology Unit, Italy. Med Mal Infect. 2010;40:268-72.
30. Gil A, San-Martín M, Carrasco P, González A. Epidemiology of severe varicella-zoster virus infection in Spain. Vaccine. 2004;22: 3947-51.